Background. Observational and retrospective clinical trial cohorts have reported conflicting results for the association of abacavir use with risk of myocardial infarction (MI), possibly related to issues that may bias estimation of treatment effects, such as time-varying confounders, informative dropout, and cohort loss due to competing events.
integrase inhibitors) [1, 2] . Lifelong treatment is required to maintain HIV suppression, improve immune function, and minimize morbidity and mortality associated with HIV disease progression. Therefore, understanding long-term risks associated with ART is paramount.
The observational Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) cohort reported that current or recent use of abacavir was associated with increased risk of myocardial infarction (MI) [3] ; data from other cohort studies and clinical trials of abacavir have provided conflicting results [4] [5] [6] [7] [8] [9] [10] [11] . For example, although analyses of the Strategies for Management of Antiretroviral Therapy (SMART) study found more than a 4-fold increase in risk [4] , a GlaxoSmithKline meta-analysis of randomized trials found no increased risk [5] and an association detected in the French Agence Nationale de Recherches sur le SIDA (ANRS) cohort was not apparent after cocaine and intravenous drug users were excluded from the analysis cohort [10] . These differences may be explained by confounding and population differences, as well as differences in analytical approach. Because abacavir was considered an attractive ART for subjects with cardiovascular disease (CVD) risk [6, [12] [13] [14] , confounding is particularly problematic [15] [16] [17] . Recent treatment guidelines now caution against the use of abacavir in subjects with high CVD risk [1, 2] , which will further confound analyses addressing this issue.
Previous analyses have focused on the increased relative risk of MI associated with abacavir. When an event is rare-as is MI in this context-even very large relative risks may have limited population-level relevance, making estimation of absolute risk difference essential.
We ascertained population level CVD risk associated with initiating ART with abacavir-containing regimens using a cohort of ART-naive persons randomly assigned ART through prospective clinical trials. Our unique cohort provides a means Figure 1 . Study population. For each parent study, shaded follow-up cells reflect the potential for participant follow-up in the parent study follow-up; unshaded cells reflect that participant follow-up is only available for participants enrolled in the AIDS Clinical Trials Group (ACTG) Longitudinally Linked Randomized Trials cohort. Missing cells reflect that, based on study enrollment, no subjects had the potential for having follow-up data available at the time that the data were frozen for analysis. Truncated at a maximum of 6 years for each individual, a total of 17,579 person-years of follow-up data were available for the cohort as a whole. a All studies randomized patients equally to each of study arm. ddI, didanosine; d4T, stavudine; EFV, efavirenz; NFV, nelfinavir; 3TC/ZDV, lamivudine/zidovudine (Combivir); IDV, indinavir; LPV/r, Kaletra; ABC/3TC/ZDV, abacavir/3TC/ZDV (Trizivir); NRTI, nucleoside reversetranscriptase inhibitor (provider choice of ZDV, d4T, or TDF made prior to randomization); ATV/r, atazanavir pharmacologically boosted with ritonavir; TDF/ FTC, tenofovir disoproxil fumarate/emtricitabine. b Because A5202 did not close to follow-up until November 2009, in the present analysis, some subjects are administratively censored prior to 96 weeks.
c Category totals do not sum to the total exclusions because subjects may have been excluded for multiple reasons.
d Subjects with a record of starting and stopping randomized antiretroviral treatment (ART) on the same day are considered to have not started randomized ART.
to address confounding and channeling bias issues of traditional observational cohorts. Our analytical approach and estimation of absolute risk places the CVD risk associated with abacavir for the treatment of ART-naive populations into a broader clinical context.
METHODS

Study Population
The AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) cohort is an observational cohort that enrolls HIV-infected persons who have been prospectively randomized to receive ART within ACTG clinical trials [18] . Patients are observed longitudinally from the start of randomized ART to determine long-term clinical, virological, and immunological outcomes. Clinical trials approved for coenrollment (parent protocols) are those providing randomized ART and at least 24 weeks of follow-up. ALLRT and its parent protocols are approved by Institutional Review Boards at all sites; all participants provide written informed consent.
This analysis includes all ART-naive individuals (defined as those with ,30 days ART exposure before study entry) initiating (22) 146 (20) 426 (23) 1075 (21) 728 (22) 347 (21) Prior IVDU 85 (10) 49 (12) 5 (9) 120 (11) 74 (10) 158 (9) 491 (10) 305 (9) 186 ( 342 (39) 298 (74) 10 (20) 544 (48) 378 (52) 797 (43) 2369 (47) 1566 (46) 803 (48) >350 331 (37) 50 (12) 26 (53) 258 (23) 138 (19) 396 (21) 1199 (24) 796 (24) 403 ( 
>100,000
429 ( (6) 1 (2) 43 (4) 27 (4) 68 (4) 186 (4) 123 (4) 63 (4) 25-29.9 269 (31) 88 (24) 16 (29) 351 (32) 222 (31) 598 (32) 1545 (31) 1069 (32) 476 (28) >30 128 (15) 36 (10) 10 (18) 152 (14) 119 (17) 734 (15) 475 (14) 259 (15) 152 (16) MDRD GFR b,c , mL/min/1.73 m 2 ,60
11 (1) 8 (2) 2 (4) 11 (1) 21 (3) 21 (1) 74 (1) 46 (1) 28 (2) H3 of hypertension 86 (10) 35 (9) 12 (22) 158 (14) 181 (25) 442 (24) 926 (18) 602 (18) 324 (19) H3 of dyslipidemia Possible 215 (24) 114 (28) 23 (42) 81 (7) 17 (2) 33 (2) 482 (10) 352 (10) 130 (8) Confirmed 13 (1) 3 (1) 1 (2) 126 (11) 135 (18) 349 (19) 627 (12) 433 (13) 194 (12) H3 of diabetes 14 (2) 15 (4) 1 (2) 46 (4) 25 (3) 95 (5) 196 (4) 122 (4) 74 (4) H3 of CVD Serious 15 (2) 3 (1) . 12 (1) 14 (2) 25 (1) 80 (2) 61 (2) 19 (1) Minor 24 (3) 21 (5) 1 (2) 32 (3) 19 (3) 78 (4) 179 (4) 119 (4) 60 (4) CVD risk factors d 2 or more 113 (13) 45 (11) 12 (22) 136 (12) 128 (18) 320 (17) 763 (15) 509 (15) (20) 34 (16) 9 (20) 146 (19) 93 (17) 222 (12) 633 (13) 633 (19) .
. . . 47 (11) 49 (9) 170 (9) 271 (5)) 271 (8)) .
ART in ALLRT parent protocols from June 1998 through November 2007 (Figure 1 ) [19] [20] [21] [22] [23] [24] [25] [26] ; subjects who did not start treatment were excluded. Patients were followed-up on their parent protocol with visits at least every 12 weeks. Subsequent to parent study completion, follow-up continued at 16 week intervals in ALLRT. The ALLRT database is cleaned and frozen annually; June 2009 datasets were used for our analyses.
Study Outcomes
The primary end point was MI. MIs were prospectively reported in each parent study and in ALLRT in the ACTG database and, during parent study follow-up, via the Division of AIDS serious adverse events (SAE) reporting system. Additionally, standardized reporting criteria that required confirmation via electrocardiogram or elevation in serum myocardial injury enzymes were added to the reporting system in December 2000. For the present analysis, all MI diagnoses identified from the ACTG and SAE databases underwent independent review by two study investigators (C.B. and J.S.) and were classified as definite, possible, or unclassifiable [27] . The investigators were provided with supporting documentation for each MI as well as with details of adverse events occurring within 6 months of the putative MI; as necessary, additional supporting documentation was reviewed. A final determination of MIs classified differently by the initial reviewers was made by two additional investigators (A.C. and S.K.). Analyses included definite and possible MIs; for subjects with multiple qualifying MIs, only the first event was included.
Statistical Considerations
The primary objective of the analysis was to estimate the shortterm and long-term relative hazard (HR) of MI between initial ART regimens with and without abacavir. Analyses were performed as intent-to-treat, including all available follow-up regardless of changes in ART. Observed follow-up was divided into monthly intervals and censored at the earliest of 6 months after the last clinic visit or 30 June 2009. For subjects who were not part of the ALLRT cohort, follow-up ended at the end of their parent study (or earlier for subjects prematurely lost to follow-up); because A5202 did not complete follow-up until November 2009, all A5202 follow-up is through that parent study. For an assessment of short-term and long-term risk, data were truncated at 1 and 6 years, respectively. Event times were defined from start of ART until first MI or non-MI death (which was considered a competing event) [28] . Cause-specific HR of MI associated with abacavir use was estimated using Cox proportional hazards regression analysis adjusted for a priori selected pretreatment patient characteristics and CVD risk factors; for a more parsimonious model, a single covariate for CVD risk was created ( Cox proportional hazards analysis assumes that censoring is not informative of the outcome of interest. Causes of censoring in our cohort that have the potential to violate this assumption include premature parent study discontinuation and decisions not to enroll into ALLRT. Stabilized inverse probability of censoring weights (IPCWs) were incorporated in the long-term analyses to account for this potential bias [30] . The weights were estimated using pooled longitudinal logistic regression to represent the inverse of the probability of remaining in observation for each month given pretreatment and past time-updated covariates. For each month, these were defined according to observed data up to the end of the previous month and included the year of follow-up, status on randomized ART, markers of HIV-1 disease status, and CVD risk factors (Table 1) . If an evaluation was not available for a given month, the covariate value defined for the prior month was carried forward. Covariate values defined based on any given clinical visit were generally carried forward over 2-5 successive monthly periods. To maximize the cohort size, categories for missing covariate information were created. Censoring weights were also used in as-treated analyses to account for censoring at discontinuation of abacavir strategy; they were not used to adjust for end of followup for non-MI deaths, because this would create an unrealistic scenario in which deaths from other causes do not occur.
To place these relative risk estimates of abacavir use into the context of absolute risk, the estimated parameters of a Cox proportional hazards model (adjusted for all statistically significant risk factors from our main analyses, P , .05) were transformed to provide estimated cumulative incidence of MI over time for a hypothetical set of individuals [31] ; 95% confidence intervals [CIs] were obtained from 1000 bootstrapped samples.
All analyses used SAS, version 9.1 (SAS Institute); graphical representations used Splus, version 6 (MathSoft).
RESULTS
A total of 5056 eligible ART-naive individuals initiated randomized ART in one of the 6 ALLRT parent studies; of these, 3381 (67%) enrolled into ALLRT (Figure 1) . As of 30 June 2009, 4640 (92%) and 1122 (22%) had 1 and 6 years follow-up, respectively; of these, 4290 (92%) and 619 (55%) remained on their randomized ART regimen. Median study follow-up was 3.1 years; median follow-up on initial ART was 2.8 years. Participants were relatively young (77% were ,45 years old), predominantly male (82%), and racially and ethnically diverse ( Table 2) .
Consistent with designs of the parent studies, approximately 44% of subjects initiated an NRTI plus NNRTI regimen, 20% initiated a regimen containing an unboosted PI, and 29% initiated a regimen containing a boosted PI; 34% initiated an abacavir-containing regimen (54% in protocol A5202, 45% in protocol A5095, and 1% in protocol A5014), 9% initiated a didanosine-containing regimen, and 21% initiated a regimen containing tenofovir disoproxil fumarate (85% in A5202 and 15% in A5142). Of 1704 subjects who initiated an abacavircontaining regimen, 74% and 44% of those still in follow-up continued to receive abacavir at 1 and 6 years, respectively; of 3352 subjects who initiated a non-abacavir-containing regimen, 2% had initiated abacavir by 1 year (8% by 6 years) ( Table 3) .
Over the first year of ART, 12 MIs were observed (3 in the abacavir group and 9 in the non-abacavir group, over 1586 and 3097 person-years (PYs) of follow-up, respectively) ( Table 3) . Twenty-four additional MIs were observed over a subsequent follow-up to 6 years (5 in the abacavir group and 19 in the nonabacavir group). The estimated cumulative MI incidence over 6 years was 1.0% and 1.2% for the abacavir and non-abacavir groups, respectively.
In unadjusted and adjusted analyses, associations between abacavir use as part of initial ART and the hazard of MI were not detected either in the short term or in the long term (unadjusted short-term analysis, P 5 .52; unadjusted long-term analysis, P 5 .21; adjusted short-term analysis, P 5 .60; adjusted long-term analysis, P 5 .25; Table 4 ). Factors associated with an increased hazard of MI in the cohort included increased age (short-term analysis, P 5 .08; long-term analysis, P , .001), a pretreatment history of 2 or more CVD risk factors (P 5 .005; P 5 .008), and current or prior smoking history (P 5 .16; P 5 .05). There was no evidence of interactions between abacavir use as part of initial treatment and age (P 5 .46; P 5 .98) or the presence of 2 or more CVD risk factors (P 5 .46; P 5 .10). No evidence of violation of proportional hazard assumption was found (P 5 .89). Lower age, male sex, minority race/ethnicity, a history of injection drug use, documented pretreatment diabetes, detectable HIV-1 RNA level, the absence of dyslipidemia, and continuing to receive an initial ART regimen were associated with a higher probability of being censored from our cohort (data not shown). However, IPCW did not substantially change our model estimates or inference. Consistent results were observed across all of our sensitivity analyses ( Table 5 ). The most extreme results came from analyses that included only contemporary regimens. This included 1677 subjects with 8 MIs in the abacavir group and 1819 subjects with 5 MIs in the nonabacavir group (hazard ratio, 1.7; P 5 .33). Figure 2 shows model-based estimates of cumulative incidence of MI over time. The results are displayed for the full cohort and most extreme sensitivity analysis. They highlight the very low absolute MI risk in this population and demonstrate that, with the exception of the very high risk group (older smokers with 2 or more CVD risk factors), a small absolute risk difference is associated with abacavir use, even when estimated from our most extreme sensitivity analysis.
To enhance the power of our study to analyze the adverse CVD effect associated with abacavir, the event of interest was expanded to include additional pre-specified serious CVD events (Table 1) . A total of 37 events were observed during the first year of ART; 97 events (including the 36 MIs) were observed over a maximum of 6 years of follow-up (17,283 PY). The Family history of CVD (vs no history) Yes 1.7 (0.4-6.9) .43 1.8 (0.9-3.9) .12 1.9 (0.9-4.2) .10
NOTE. CI, confidence interval; CVD, cardiovascular disease. a Weighted using inverse probability of censoring weights for which lower age, male sex, minority race/ethnicity, a history of IV drug use, documented pretreatment diabetes, detectable HIV-1 RNA level, the absence of dyslipidemia and remaining on initial ART regimen were all associated with a higher probability censoring. b Adjusted for other covariates listed. NOTE. ART, antiretroviral treatment; CI, confidence interval; MI, myocardial infarction; PY, person-years. a For subjects randomized to an abacavir-containing regimen, strategy discontinuation is defined as discontinuation of abacavir; for subjects randomized to a nonabacavir-containing regimen, it is defined as initiation of an abacavir-containing regimen.
b Follow-up is included from start of ART until first event, death, or last evaluation plus 6 months.
c The median follow-up time (in years) at MI event across subjects with MI.
d These events are a subset of those included in the overall total number of events.
e The median years of off-strategy follow-up before MI (across subjects with MI after discontinuation of their randomized abacavir strategy). findings from these analyses gave results that were generally consistent with those for MI events (Table 5) .
DISCUSSION
This analysis of 5056 individuals who initiated ART in 6 randomized clinical trials aims to contribute to clinical decisionmaking with respect to risk for CVD events and choice of initial ART regimens, specifically with respect to abacavir. Overall MI incidence in our cohort was 2.1 events per 1000 PY (95% CI, 1.8-3.7), compared with between 3.1-5.0 events per 1000 PY from prior studies in this area [3, [5] [6] [7] , demonstrating a low absolute risk of MI in this typical HIV-1 cohort of individuals initiating ART. We did not find evidence of increased shortterm or long-term risk of MI or of serious CVD events associated with abacavir use as part of initial ART. This result was robust in as-treated analysis and a range of sensitivity analyses. An increased risk of MI events was detected for persons of older age and with classic CVD risk factors, such as smoking and prior CVD history. Our analysis was unique in including a long-term cohort of HIV-1-infected persons initiating ART in randomized clinical trials, and our intent-to-treat analysis with adjustment only for pretreatment covariates provides a broad population-level perspective of the risk of MI associated with abacavir-containing initial regimens. This analytic framework contrasts with use of time-updated covariates for drug exposure and/or risk factors [4, 6, 7, 10] or censoring follow-up at discontinuation of abacavir [5] that have been used in other studies. Although such studies are attractive for their simplicity, in the presence of related and temporally confounded effects, adjustment for timeupdated effects is likely to induce or attenuate the estimated risk associated with the exposure of interest [16, 33] . Although the as-treated censoring approach is also often preferred because it is seen to more clearly isolate the direct effect of the exposure of NOTE. All estimates are adjusted with covariates as listed in Table 4 ; 6-year estimates are based on inverse probability of censoring weights (IPCW) analysis. ABC, abacavir; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; MI, myocardial infarction; PI, protease inhibitor; PY, person-years.
a Model fitting for as-treated analyses include IPCW for discontinuation of abacavir strategy.
b Contemporary regimens are defined as those containing either a nonnucleoside reverse-transcriptase inhibitor (NNRTI) or ritonavir boosted PI with 2 or 3 NRTIs not including stavudine.
Continue from previous page. individuals with smoking and CVD risk factors as described for A-D. Cumulative incidence is based on IPCW Cox proportional hazards model including abacavir use and significant covariates (P ,.05) from Table 4 ; 95% confidence intervals at 1 and 6 years are from 1000 bootstrapped samples. Solid lines are based on results from the full cohort; dotted lines are based on the sensitivity analyses including only contemporary regimens. Gray lines with circles indicate the cohort randomized to an abacavir regimen; black lines with squares indicate a non-abacavir-containing regimen.
interest (in this case, abacavir use), not only does this have the potential to introduce an informative censoring bias, it is important to note that such censoring changes the question being addressed to one that is a purely hypothetical scenario: estimating the effect of abacavir use under the condition that, once treatment with abacavir is started, it is never discontinued. Because toxicity issues, individual ART fatigue, and regimen failure dictate that most regimens will at some time be discontinued or modified, the resulting parameter estimates do not relate to reallife situations. For completeness, we performed an as-treated analysis as a sensitivity analysis and found consistent conclusions.
A criticism of the intent-to-treat approach is that, although it is suited for the analysis of randomized trials because of crossover between strategies, it is not relevant in the context of understanding the effect of specific drugs in cohort data. On the contrary, such inference remains critically important in understanding population-level drug effects that are implicitly adjusted for prescribing biases and drug-taking behavior of the population under study-in our case a relatively young (median age, 37 years) cohort with well-controlled HIV disease over the course of follow-up-overall, 83% of the total follow-up period was spent with HIV-1 RNA levels ,400 copies/mL, and 63% was spent with CD4 1 cell counts .350 cells/mm 3 . IPCW methodology was used in our long-term analysis to investigate the influence of informative censoring bias due to premature study discontinuation and individuals not enrolling into ALLRT. Noninformative censoring is a fundamental assumption of any survival analysis that is often not fully scrutinized. Assuming that subjects with a given covariate history who are no longer in follow-up can be represented by similar subjects who remain in follow-up, IPCWs adjust for potential informative censoring by weighting uncensored data to create a pseudo-population in which censoring does not exist [33, 34] . IPCW methodology did not dramatically impact our results. This could mean that informative censoring is not a concern for this analysis, that informative censoring exists but differential effects cancel each other out, or that our model for informative censoring has failed to adjust for the key variables that drive the informative censoring. This latter scenario reflects the failure of the key assumption of no unmeasured confounding that underpins all IPCW methodology. Of note, almost half of the censoring in our analysis was administrative, which can reasonably be assumed to be noninformative.
One study limitation concerns the power to detect a difference between abacavir-containing and non-abacavir-containing initial regimens, because only 36 MI events were observed during 6 years (17,404 PY) of follow-up. Furthermore, some of the comparator groups contained ART agents that are no longer commonly used and other agents that may have been implicated with adverse lipid profiles or increased CVD risk [1, 35, 36] . However, studies of similar size to our own have demonstrated significant results [4, 11] , and our sensitivity analyses that restricted contemporary regimens (those including 2 or 3 NRTIs with NNRTI or boosted-PI) and excluded regimens that have also been implicated with increased CVD risk provided consistent conclusions to our main result.
The strength of our cohort is randomized ART assignment that lessens the potential for confounding and channeling bias that can complicate interpretation of treatment associations from observational data. These are particularly problematic for investigating MI risk with abacavir, because past prescribing practices favored abacavir regimens for individuals at high CVD risk [6, [12] [13] [14] . Because only 3 of the studies included in our analysis involved a randomized abacavir strategy, we were not able to estimate the direct effect of the abacavir randomization in a classic meta-analysis sense [37] . Rather, our approach relies on the assumption that the relative effect of interest is consistent across included studies. That is, the effect of abacavir in nonabacavir studies-had they included randomized abacavir-is assumed to be the same as that in the studies with randomized abacavir. Such an assumption is reasonable. All of the studies were conducted at the same clinical sites, had similar entry criteria, and, with the exception of a brief period early in followup, used the same mechanism for MI identification. Furthermore, sensitivity analyses restricting the cohort only to studies including randomized abacavir were consistent with findings of the entire cohort.
In conclusion, we studied individuals who initiated ART with and without abacavir as part of randomized clinical trials. Over a period of up to 6 years from ART initiation, we observed a very low absolute risk of MI and serious CVD events. We found no evidence of an increased risk of MI or serious CVD associated with the use of abacavir as part of initial treatment over the first year of ART and the longer term that was consistent in as-treated and sensitivity analyses. Classic CVD risk factors were the strongest predictors of MI and serious CVD events and should be the main focus in assessing CVD risk among HIV-1 infected individuals.
